eli lilly glp-1 drugs ad war leads to lawsuit by Novo Nordisk, claiming misleads The Future of GLP-1 Drugs

doi:10.3233/JAD-180263CrossRefGoogle ScholarPubMed Aman, MG, Hollway, JA, Veenstra-VanderWeele, J, et al

The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough

If you experience persistent side effects, chest pain, fainting, or worsening breathing, stop the medication and seek emergency care

Identification of a cryptic nucleolar-localization signal in MDM2